Pemakaian Nikotinamide Dalam Penanganan Hiperfosfatemia Pada Pasien Hemodialisis
48
DAFTAR PUSTAKA
1. Suwitra K. Peran gangguan fosfat dan kalsium pada morbiditas dan
mortalitas penyakit ginjal kronis. The 6th Jakarta Nephrology &
Hypertension course and Symposium on Hypertension. Edisi 1.
PERNEFRI; 2006. Hlm 23-30.
2. Ketteler M. Phosphorus control in chronic kidney disease. European Renal
Disease. 2007; 24-6.
3. Vasantha J, Soundararajan P, Vanitharani N, Kannan G, Thennarasu P,
Neenu G Reddy U. Safety and efficacy of nicotinamide in the management
of hyperphosphatemia in patients on hemodialysis. Indian J nephrol.
2011;21(4):245-9.
4. Muller D, Mehling H, Otto B, Bergmann-Lips R, Luft F, Jordan J, Kettritz
R. Niacin lowers serum phosphate and increase HDL cholesterol in
dialysis patients. Clin J Am Soc Nephrol. 2007;2:1249-54.
5. Cheng SC, Young DO, Huang Y, Delmez JA, Coyne DW. A randomized,
double blind, placebo-controlled trial of niacinamide for reduction of
phosphorus in hemodialysis patients. Clin J Am Soc Nephrol. 2008;3:
1131-8.
6. KDIGO clinical practice guideline for the diagnosis, evaluation,
prevention and treatment of chronic kidney disease-mineral and bone
disorder (CKD-MBD). Kidney International. 2009;113:S50-S99.
7. Konsensus gangguan mineral dan tulang pada penyakit ginjal kronik
(GMT-PGK). Edisi 1. Perhimpunan nefrologi Indonesia (PERNEFRI).
2009. Hlm 1-78.
8. Lederer E, Batuman V. Hyperphosphatemia. Dalam: Batuman V, Editor.
Medscape Reference. 2012. Available at: www.medscape.org. Cited on
Oct, 28 2012.
9. Hutchison AJ, Smith CP and Brenchley PE. Pharmacology, efficacy and
safety of oral phosphate binders. Dalam: Ireland R, Editor. Medscape
Referance. 2011. Available at www.medscape.org. Cited on Oct,28 2012.
29
Universitas Sumatera Utara
49
10. Lenglet A, Liabeuf S, Guffroy P, Fournier A, Brazier M, Massy ZA. Use
of nicotinamide to treat hyperphosphatemia in dialysis patient.
Springerlink. 2013;13:165-73.
11. Royal
Society
of
Chemistry.
Nicotinamide.
Available
at:
www.chemspider.com/chemical-structure.911.html. Cited on Oct,28 2012.
12. Schiavi SC, Tang W, Bracken C, O’Brien SP, Song W, Boulanger J, et al.
Npt2b deletion attenuates hyperphosphatemia associated with CKD. J Am
Soc Nephrol. 2012;23:1691–1700.
13. Slominska EM, Kowalik K, Smolenski RT, Szolkiewicz M, Rutkowski P,
Rutkowski B, et al. Accumulation of poly(ADPribose) polymerase
inhibitors in children with chronic renal failure. Pediatr Nephrol.
2006;21:800–6.
14. Sampathkumar K. Niacin and analogs for phosphate control in dialysis–
perspective from a developing country. Int Urol Nephrol. 2009;41:913–8.
15. Sampathkumar K, Selvam M, Sooraj YS, Gowthaman S,Ajeshkumar
RNP. Extended release nicotinic acid—a novel oral agent for phosphate
control. Int Urol Nephrol. 2006;38:171–74.
16. Restrepo Valencia CA, Cruz J. Safety and effectiveness of nicotinic acid
in the management of patients with chronic renal disease and
hyperlipidemia associated to hyperphosphatemia. Nefrologia. 2008;28:61–
66.
17. Maccubbin D, Tipping D, Kuznetsova O, Hanlon WA, Bostom AG.
Hypophosphatemic effect of niacin in patients without renal failure: a
randomized trial. Clin J Am Soc Nephrol. 2010;5: 582–89.
18. Takahashi Y, Tanaka A, Nakamura T, Fukuwatari T, Shibata K, Shimada
N, et al. Nicotinamide suppresses hyperphosphatemia in hemodialysis
patients. Kidney Int. 2004;65:1099–104.
19. Young D.O, Cheng SC, Delmez JA. The effect of oral niacinamide on
plasma phosphorus levels in peritoneal dialysis patients. Perit Dial Int.
2009;29:562-7.
20. Shahbazian H, Mohtashami AZ, Ghorbani A, Abbaspour MR, Musavi
SSB, Hayati F, Lashkarara GR. Oral nicotinamide reduces serum
Universitas Sumatera Utara
50
phosphorus, increase HDL, and induces thrombocytopenia in hemodialysis
patients:
a
double-blind
randomized
clinical
trial.
Nefrologia.
2011;31(1):58-65.
21. Gale EAM, Bingley PJ, Emmett CL, Collier T. European Nicotinamide
Diabetes Intervention Trial (ENDIT): a randomised controlled trial of
intervention before the onset of type 1 diabetes. Lancet. 2004;363:925–31.
22. Delanaye P, Weekers L, Krzesinski JM. Diarrhea induced by high doses of
nicotinamide in dialysis patients. Kidney international. 2006;69(10):1914.
23. Rottembourg JB, Launay-Vacher V, Massard J. Thrombocytopenia
induced by nicotinamide in hemodialysis patients. Kidney Int.
2005;68:2911–12.
24. Madiyono, B, Moeslichan, S, Sastroasmoro, S et al.
Perkiraan besar
sampel. Dalam: Sastroasmoro S, Ismael S, Penyunting. Dasar-dasar
Metodologi penelitian klinis. Edisi 3. Sagung Seto 2010. Hlm 302-12.
25. Allam S, El-hamamsy M, El Sharkawy M. The effect of coadministration
of
nicotinamide
and
calcium-based
phosphate
binder
on
hyperphosphatemia in patients undergoing hemodialysis. Advances in
natural science. 2012;5(1):1-9.
26. Rottembourg JB, Launay-Vacher V, Massard J. Thrombocytopenia
induced
bt
nicotinamide
in
hemodialysis
patients.
Kidney
Int.
2005;68:2911-12.
Universitas Sumatera Utara
DAFTAR PUSTAKA
1. Suwitra K. Peran gangguan fosfat dan kalsium pada morbiditas dan
mortalitas penyakit ginjal kronis. The 6th Jakarta Nephrology &
Hypertension course and Symposium on Hypertension. Edisi 1.
PERNEFRI; 2006. Hlm 23-30.
2. Ketteler M. Phosphorus control in chronic kidney disease. European Renal
Disease. 2007; 24-6.
3. Vasantha J, Soundararajan P, Vanitharani N, Kannan G, Thennarasu P,
Neenu G Reddy U. Safety and efficacy of nicotinamide in the management
of hyperphosphatemia in patients on hemodialysis. Indian J nephrol.
2011;21(4):245-9.
4. Muller D, Mehling H, Otto B, Bergmann-Lips R, Luft F, Jordan J, Kettritz
R. Niacin lowers serum phosphate and increase HDL cholesterol in
dialysis patients. Clin J Am Soc Nephrol. 2007;2:1249-54.
5. Cheng SC, Young DO, Huang Y, Delmez JA, Coyne DW. A randomized,
double blind, placebo-controlled trial of niacinamide for reduction of
phosphorus in hemodialysis patients. Clin J Am Soc Nephrol. 2008;3:
1131-8.
6. KDIGO clinical practice guideline for the diagnosis, evaluation,
prevention and treatment of chronic kidney disease-mineral and bone
disorder (CKD-MBD). Kidney International. 2009;113:S50-S99.
7. Konsensus gangguan mineral dan tulang pada penyakit ginjal kronik
(GMT-PGK). Edisi 1. Perhimpunan nefrologi Indonesia (PERNEFRI).
2009. Hlm 1-78.
8. Lederer E, Batuman V. Hyperphosphatemia. Dalam: Batuman V, Editor.
Medscape Reference. 2012. Available at: www.medscape.org. Cited on
Oct, 28 2012.
9. Hutchison AJ, Smith CP and Brenchley PE. Pharmacology, efficacy and
safety of oral phosphate binders. Dalam: Ireland R, Editor. Medscape
Referance. 2011. Available at www.medscape.org. Cited on Oct,28 2012.
29
Universitas Sumatera Utara
49
10. Lenglet A, Liabeuf S, Guffroy P, Fournier A, Brazier M, Massy ZA. Use
of nicotinamide to treat hyperphosphatemia in dialysis patient.
Springerlink. 2013;13:165-73.
11. Royal
Society
of
Chemistry.
Nicotinamide.
Available
at:
www.chemspider.com/chemical-structure.911.html. Cited on Oct,28 2012.
12. Schiavi SC, Tang W, Bracken C, O’Brien SP, Song W, Boulanger J, et al.
Npt2b deletion attenuates hyperphosphatemia associated with CKD. J Am
Soc Nephrol. 2012;23:1691–1700.
13. Slominska EM, Kowalik K, Smolenski RT, Szolkiewicz M, Rutkowski P,
Rutkowski B, et al. Accumulation of poly(ADPribose) polymerase
inhibitors in children with chronic renal failure. Pediatr Nephrol.
2006;21:800–6.
14. Sampathkumar K. Niacin and analogs for phosphate control in dialysis–
perspective from a developing country. Int Urol Nephrol. 2009;41:913–8.
15. Sampathkumar K, Selvam M, Sooraj YS, Gowthaman S,Ajeshkumar
RNP. Extended release nicotinic acid—a novel oral agent for phosphate
control. Int Urol Nephrol. 2006;38:171–74.
16. Restrepo Valencia CA, Cruz J. Safety and effectiveness of nicotinic acid
in the management of patients with chronic renal disease and
hyperlipidemia associated to hyperphosphatemia. Nefrologia. 2008;28:61–
66.
17. Maccubbin D, Tipping D, Kuznetsova O, Hanlon WA, Bostom AG.
Hypophosphatemic effect of niacin in patients without renal failure: a
randomized trial. Clin J Am Soc Nephrol. 2010;5: 582–89.
18. Takahashi Y, Tanaka A, Nakamura T, Fukuwatari T, Shibata K, Shimada
N, et al. Nicotinamide suppresses hyperphosphatemia in hemodialysis
patients. Kidney Int. 2004;65:1099–104.
19. Young D.O, Cheng SC, Delmez JA. The effect of oral niacinamide on
plasma phosphorus levels in peritoneal dialysis patients. Perit Dial Int.
2009;29:562-7.
20. Shahbazian H, Mohtashami AZ, Ghorbani A, Abbaspour MR, Musavi
SSB, Hayati F, Lashkarara GR. Oral nicotinamide reduces serum
Universitas Sumatera Utara
50
phosphorus, increase HDL, and induces thrombocytopenia in hemodialysis
patients:
a
double-blind
randomized
clinical
trial.
Nefrologia.
2011;31(1):58-65.
21. Gale EAM, Bingley PJ, Emmett CL, Collier T. European Nicotinamide
Diabetes Intervention Trial (ENDIT): a randomised controlled trial of
intervention before the onset of type 1 diabetes. Lancet. 2004;363:925–31.
22. Delanaye P, Weekers L, Krzesinski JM. Diarrhea induced by high doses of
nicotinamide in dialysis patients. Kidney international. 2006;69(10):1914.
23. Rottembourg JB, Launay-Vacher V, Massard J. Thrombocytopenia
induced by nicotinamide in hemodialysis patients. Kidney Int.
2005;68:2911–12.
24. Madiyono, B, Moeslichan, S, Sastroasmoro, S et al.
Perkiraan besar
sampel. Dalam: Sastroasmoro S, Ismael S, Penyunting. Dasar-dasar
Metodologi penelitian klinis. Edisi 3. Sagung Seto 2010. Hlm 302-12.
25. Allam S, El-hamamsy M, El Sharkawy M. The effect of coadministration
of
nicotinamide
and
calcium-based
phosphate
binder
on
hyperphosphatemia in patients undergoing hemodialysis. Advances in
natural science. 2012;5(1):1-9.
26. Rottembourg JB, Launay-Vacher V, Massard J. Thrombocytopenia
induced
bt
nicotinamide
in
hemodialysis
patients.
Kidney
Int.
2005;68:2911-12.
Universitas Sumatera Utara